Literature DB >> 10208616

Propionibacterium acnes: interaction with complement and development of an enzyme-linked immunoassay for the detection of antibody.

C G Burkhart1, J Cantrill, C L Butcher, P F Lehmann.   

Abstract

OBJECTIVE: To characterize the immune response to Propionibacterium acnes in acne patients.
DESIGN: Comparison of serologic responses in acne and normal patients using counterimmunoelectrophoresis for antibody and an enzyme-linked immunosorbent assay (ELISA) to detect immunoglobulin G (IgG) antibody.
SETTING: The serum of acne and nonacne patients from the Dermatology Clinic at the Medical College of Ohio was utilized for analysis.
RESULTS: Using counterimmunoelectrophoresis, antibody was detected in 13 of 20 acne patients. The antigen was detectable as an anion in the barbital buffer at pH 8.2, strongly suggesting a carbohydrate component. By ELISA, the antibody proved to be IgG, and the bacteria and its water-soluble fractions were capable of fixing complement.
CONCLUSIONS: The primary instigator of inflammation in acne vulgaris is an immunologic reaction to extracellular products of P. acnes. The immunologic response involves both humoral and cell-mediated pathways. The antibodies to P. acnes have not been characterized fully, although they are largely of the IgG class. We have further characterized the dominant antigen to have a carbohydrate component.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208616

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  2 in total

1.  Tretinoin: A Review of Its Anti-inflammatory Properties in the Treatment of Acne.

Authors:  Nicholas Schmidt; Eugene H Gans
Journal:  J Clin Aesthet Dermatol       Date:  2011-11

2.  Quantification of the antibody response to Propionibacterium acnes in a patient with prosthetic valve endocarditis: - a case report.

Authors:  T Herren; M A Middendorp; R Zbinden
Journal:  BMC Infect Dis       Date:  2016-04-29       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.